Sailor

SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Homology Medicines, Inc., of Class Action Lawsuit and Upcoming Deadline – FIXX

Retrieved on: 
Thursday, April 7, 2022
Company, Risk, LLP, Letter, PKU, Central District, NASDAQ, Phenix, Leibniz Centre for Tropical Marine Research, Complaint, Sailor, Lists of action films, Pomerantz, District court, Phenylketonuria, Program, Court, Lists of schools in England, Food, Lists of diseases, Securities Exchange Act of 1934, Person, GLOBE, News, Ext, Awareness, SEC Rule 10b-5, Social media, Patient, Pharmaceutical industry, Animal

NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. (Homology or the Company) (NASDAQ: FIXX) and certain of its officers.

Key Points: 
  • NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. (Homology or the Company) (NASDAQ: FIXX) and certain of its officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

HOMOLOGY MEDICINES, INC. (NASDAQ: FIXX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Homology Medicines, Inc. (NASDAQ: FIXX)

Retrieved on: 
Thursday, April 7, 2022
Company, Risk, Advertising, Letter, Central District, PKU, NASDAQ, NEW, Phenix, Leibniz Centre for Tropical Marine Research, Sailor, Investment, District court, Patient, Phenylketonuria, Program, Court, Lists of schools in England, Food, Securities Exchange Act of 1934, GLOBE, Lists of action films, News, Labour government, Awareness, FDA, Social media, The Legal 500, Pharmaceutical industry, Animal, Security (finance)

NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) between June 10, 2019 and February 18, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Central District of California and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Central District of California and alleges violations of the Securities Exchange Act of 1934.
  • Homology, a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Embark, Homology, and Lucid and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, April 7, 2022
Company, Risk, Letter, PKU, NASDAQ, State, Phenix, Alfred Wegener Institute for Polar and Marine Research, Sailor, Liver function tests, Phenylketonuria, Program, Lists of schools in England, Food, Combination, Industry, Regulation of tobacco by the U.S. Food and Drug Administration, Bear's Cave (Erpfingen), GLOBE, Business architecture, News, Awareness, Social media, Technology, Acquisition, Patient, Bears' Cave, Financial services, Renewable energy, Audit, Pharmaceutical industry, Animal, Lucid, P.C, Homology

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and compliance policies.

Key Points: 
  • The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and compliance policies.
  • On January 6, 2022, The Bear Cave published a short report entitled Problems at Embark Technology (EMBK) (the Bear Cave Report).
  • On this news, Embarks stock price fell $1.37 per share, or 16.75%, to close at $6.81 per share on January 6, 2022.
  • For more information on the Lucid class action go to: https://bespc.com/cases/LCID
    About Bragar Eagel & Squire, P.C.

HOMOLOGY DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Homology Medicines, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, April 6, 2022
Legal, Professional Services, Company, Risk, Letter, Central District, PKU, NASDAQ, Phenix, Bornö Marine Research Station, Sailor, Jeanne Eagels, Liver function tests, District court, Phenylketonuria, Program, Telephone, Court, Lists of schools in England, Food, Person, Regulation of tobacco by the U.S. Food and Drug Administration, P.C, News, Awareness, Social media, Patient, Pharmaceutical industry, Homology

Investors have until May 24, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until May 24, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Homology, a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases.
  • On June 10, 2019, Homology issued a press release announcing that it had commenced enrollment of the HMI-102 Trial.
  • The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.

FIXX ALERT: Investors with Substantial Losses Have Opportunity to Lead Homology Medicines, Inc. Class Action Lawsuit

Retrieved on: 
Saturday, April 2, 2022
Legal, Professional Services, Risk, Letter, PKU, NASDAQ, Private Securities Litigation Reform Act, Phenix, Leibniz Centre for Tropical Marine Research, Sailor, Phenylketonuria, Program, Food, Lists of schools in England, SEC, Securities Exchange Act of 1934, Enron, Company, News, CASE, Awareness, Homology, FDA, Lawyer, Social media, History, Tobacco, Pharmaceutical industry

If you suffered significant losses and wish to serve as lead plaintiff of the Homology Medicines class action lawsuit, please provide your information by clicking here .

Key Points: 
  • If you suffered significant losses and wish to serve as lead plaintiff of the Homology Medicines class action lawsuit, please provide your information by clicking here .
  • Lead plaintiff motions for the Homology Medicines class action lawsuit must be filed with the court no later than May 24, 2022.
  • THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Homology Medicines securities during the Class Period to seek appointment as lead plaintiff in the Homology Medicines class action lawsuit.
  • A lead plaintiff acts on behalf of all other class members in directing the class action lawsuit.

HOMOLOGY MEDICINES, INC. (NASDAQ: FIXX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Homology Medicines, Inc. (NASDAQ: FIXX)

Retrieved on: 
Thursday, March 31, 2022
Company, Risk, Advertising, Letter, Central District, PKU, NASDAQ, Phenix, Leibniz Centre for Tropical Marine Research, Sailor, District court, Patient, Phenylketonuria, Program, Court, Lists of schools in England, Food, Securities Exchange Act of 1934, GLOBE, Lists of action films, News, Labour government, Awareness, FDA, Social media, The Legal 500, Pharmaceutical industry, Animal, Security (finance)

On June 10, 2019, Homology issued a press release announcing that it had commenced enrollment of the HMI-102 Trial.

Key Points: 
  • On June 10, 2019, Homology issued a press release announcing that it had commenced enrollment of the HMI-102 Trial.
  • Throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and compliance policies.
  • If you purchased FIXX securities, and/or would like to discuss your legal rights and options please visit Homology Medicines, Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Homology Medicines, Inc., of Class Action Lawsuit and Upcoming Deadline – FIXX

Retrieved on: 
Thursday, March 31, 2022
Company, Risk, LLP, Letter, PKU, Central District, NASDAQ, Phenix, Leibniz Centre for Tropical Marine Research, Complaint, Sailor, Lists of action films, Pomerantz, District court, Phenylketonuria, Program, Court, Lists of schools in England, Food, Lists of diseases, Securities Exchange Act of 1934, Person, GLOBE, News, Ext, Awareness, SEC Rule 10b-5, Social media, Patient, Pharmaceutical industry, Animal

NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. (Homology or the Company) (NASDAQ: FIXX) and certain of its officers.

Key Points: 
  • NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. (Homology or the Company) (NASDAQ: FIXX) and certain of its officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Homology Medicines, Inc. (FIXX)

Retrieved on: 
Monday, March 28, 2022
Company, Risk, Letter, Central District, NASDAQ, Phenix, Alfred Wegener Institute for Polar and Marine Research, Sailor, Complaint, District court, Phenylketonuria, Program, Food, GLOBE, News, Awareness, Social media, Pharmaceutical industry, Homology

Investors who purchased or otherwise acquired shares of Homology should contact the Firm prior to the May 24, 2022 lead plaintiff motion deadline.

Key Points: 
  • Investors who purchased or otherwise acquired shares of Homology should contact the Firm prior to the May 24, 2022 lead plaintiff motion deadline.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq.
  • of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected] .

ALERT: Homology Medicines, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - FIXX

Retrieved on: 
Tuesday, March 29, 2022
Legal, Professional Services, Risk, Letter, PKU, NASDAQ, Private Securities Litigation Reform Act, Phenix, Leibniz Centre for Tropical Marine Research, Sailor, Phenylketonuria, Program, Food, Lists of schools in England, SEC, Securities Exchange Act of 1934, Enron, Company, News, CASE, Awareness, Homology, FDA, Lawyer, Social media, History, Pharmaceutical industry, Tobacco

Commenced on March 25, 2022, the Homology Medicines class action lawsuit charges Homology Medicines as well as certain of its top executive officers with violations of the Securities Exchange Act of 1934.

Key Points: 
  • Commenced on March 25, 2022, the Homology Medicines class action lawsuit charges Homology Medicines as well as certain of its top executive officers with violations of the Securities Exchange Act of 1934.
  • If you suffered significant losses and wish to serve as lead plaintiff of the Homology Medicines class action lawsuit, please provide your information by clicking here .
  • Lead plaintiff motions for the Homology Medicines class action lawsuit must be filed with the court no later than May 24, 2022.
  • THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Homology Medicines securities during the Class Period to seek appointment as lead plaintiff in the Homology Medicines class action lawsuit.

SeaSpine® Announces Full Commercial Launch of NorthStar™ Facet Fusion and Limited Commercial Launch of FLASH™ Navigation Lumbar Facet Fusion

Retrieved on: 
Tuesday, March 1, 2022
Hip, CSRS, Neurosurgery, Patient, Surgeon, Spinal fusion, Security (finance), OCT, U.S. Securities and Exchange Commission, Technology, News, Solution, Development, MIS, Orthopedic surgery, MD, National Center for Spinal Disorders, SPNE, Sailor, Spine, NorthStar, GLOBE, NASDAQ, 3D printing, Dentistry, Risk management

CARLSBAD, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of NorthStar Cervical Facet Fusion and the limited commercial launch of FLASH Navigation Lumbar Facet Fusion, the latest orthobiologics solutions tailored to specific procedural needs.

Key Points: 
  • CARLSBAD, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of NorthStar Cervical Facet Fusion and the limited commercial launch of FLASH Navigation Lumbar Facet Fusion, the latest orthobiologics solutions tailored to specific procedural needs.
  • NorthStar Facet Fusion is an all-in-one solution that combines OsteoStrand DBM Fiber cervical pellets and disposable facet prep instrumentation, all of which is optimized for use with NorthStar OCT, SeaSpines posterior cervical fixation system that entered full commercial launch in October 2021.
  • SeaSpines FLASH Navigation Lumbar Facet Fusion features instruments that are designed to target and deliver OsteoStrand Plus DBM Fiber pellets within the facet joint during MIS procedures.
  • This limited commercial launch marks the first SeaSpine procedural system developed and integrated with 7D Technology.